Protagonist Therapeutics

Yahoo Finance • 23 days ago

Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera

(RTTNews) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV). The data, presented at the 67th American Society... Full story

Yahoo Finance • last month

Protagonist Therapeutics Reaches Analyst Target Price

In recent trading, shares of Protagonist Therapeutics Inc (Symbol: PTGX) have crossed above the average analyst 12-month target price of $89.77, changing hands for $89.86/share. When a stock reaches the target an analyst has set, the anal... Full story

Yahoo Finance • 2 months ago

Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial

Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Protagonist Therapeutics falls amid a report J&J deal price may be lower

[Johnson & Johnson offices in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]) dropped 5% after a report that the Johnson & Johnson (NYSE:JN... Full story

Yahoo Finance • 3 months ago

J&J in talks to acquire Protagonist Therapeutics

Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current collaboration, as reported by The Wall Street Journal (WSJ). While a deal is not certain, the acquisition could signif... Full story

Yahoo Finance • 3 months ago

Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more

Here's a list of key deals reported across sectors this week: * Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall... Full story

Yahoo Finance • 3 months ago

Protagonist Stock Surges on Johnson & Johnson Report

Protagonist Therapeutics shares soared more than 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more ... Continue Reading Visualizza comme... Full story

Yahoo Finance • 3 months ago

Trump's China tariff threat sinks stocks, Applied Digital surges

Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Decline Friday Afternoon

Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Top Midday Gainers

Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more

Check out the companies making the biggest moves midday: Rare earth stocks — The group rose broadly after President Donald Trump said China was holding the world "captive" over the minerals, threatening countermeasures. MP Materials traded... Full story

Yahoo Finance • 3 months ago

Protagonist Therapeutics stock surges after J&J acquisition talks report

Investing.com -- Protagonist Therapeutics (NASDAQ:PTGX) stock spiked 10% before being halted for volatility after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the biotech company. The potential... Full story

Yahoo Finance • 3 months ago

J&J reportedly in talks to buy Protagonist

Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ [https://s... Full story

Yahoo Finance • 3 months ago

Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says

Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

We Did The Math IJR Can Go To $133

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Protagonist therapeutics CEO Patel sells $570k in stock

Protagonist Therapeutics (NASDAQ:PTGX) President and CEO Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock on July 25, 2025, at prices ranging from $54.75 to $54.82, for a total value of $570,533. The sale comes as the $3.48 billi... Full story

Yahoo Finance • 5 months ago

XSMO's Underlying Holdings Could Mean 15% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head... Full story

Yahoo Finance • 6 months ago

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism. Continue Reading View Comments... Full story

Yahoo Finance • 6 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story